Published on 7 Nov 2023 on Simply Wall St. via Yahoo Finance

Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Just Trimmed Their Revenue Forecasts By 13%

One thing we could say about the analysts on Bicycle Therapeutics plc (NASDAQ:BCYC) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

After the downgrade, the 13 analysts covering Bicycle Therapeutics are now predicting revenues of US$32m in 2024. If met, this would reflect a sizeable 27% improvement in sales compared to the last 12 months. Losses are supposed to balloon 49% to US$5.80 per share. However, before this estimates update, the consensus had been expecting revenues of US$36m and US$5.83 per share in losses. So there's definitely been a change in sentiment in this update, with the analysts administering a substantial haircut to next year's revenue estimates, while at the same time holding losses per share steady.

Check out our latest analysis for Bicycle Therapeutics